An estimated 11.3 million new HSV-2 infections occurred globally in 2016. Viral shedding happens frequently without visible symptoms, but daily suppressive therapy can cut HSV-1 transmission risk by roughly half in discordant couples.
Key Takeaways
- CDC notes that antiviral therapy is effective for both episodic treatment and daily suppressive therapy (clinical efficacy basis)
- From 2013 to 2018, the rate of outpatient visits for herpes simplex increased in the US by 9% (MEPS utilization trends)
- In a UK study using GUMCAD data, genital herpes diagnoses per 100,000 population increased over the early 2000s and remained substantial into the period after (public health surveillance)
- In a randomized trial, the hazard/odds of transmission decreased when suppressive therapy was used compared with placebo in HSV-2 discordant couples
- Risk reduction for HSV-1 genital transmission was about 50% with daily suppressive acyclovir (randomized controlled trial evidence)
- Plasma HSV-2 DNA shedding occurs frequently even without visible lesions, with shedding detected on many days in infected individuals (study-based observation)
- A systematic review of randomized trials estimated that suppressive therapy for HSV reduces shedding days by about half in recurrent genital HSV
- In a randomized trial, weekly condom use reduced HSV-2 incidence by 30% among couples where the index partner had HSV-2
- 11.3 million new HSV-2 infections occurred globally in 2016 (2016 global estimate)
- 720,000 new HSV-1 genital infections occurred annually in the United States (modeled estimate)
- In a seroepidemiology study, HSV-2 prevalence was 18% among US women aged 14–49 in NHANES estimates (population prevalence percentage)
- In a systematic review, HSV-2 infection increased the risk of HIV acquisition by 2.2x overall (pooled estimate)
- In a pooled analysis, HSV-2–infected individuals had a 2.6x higher risk of acquiring HIV compared with HSV-2–uninfected individuals (pooled estimate)
- In a phase 3 prevention trial, genital herpes was associated with increased HIV incidence risk in participants (hazard ratio 1.5)
- In a randomized placebo-controlled trial, acyclovir suppressed HSV reactivation as measured by reduction in lesion days by 0.4 days per month (difference vs placebo)
Daily suppressive antivirals and condoms substantially cut herpes transmission, even without symptoms.
Related reading
01 · Category
Industry Trends4 stats
01
CDC notes that antiviral therapy is effective for both episodic treatment and daily suppressive therapy (clinical efficacy basis)
02
From 2013 to 2018, the rate of outpatient visits for herpes simplex increased in the US by 9% (MEPS utilization trends)
03
In a UK study using GUMCAD data, genital herpes diagnoses per 100,000 population increased over the early 2000s and remained substantial into the period after (public health surveillance)
04
In England, the proportion of new STI diagnoses attributed to herpes rose during the 2008–2012 period in national surveillance reporting (public health trend dataset described in paper)
Interpretation
Industry Trends Interpretation
Across recent national and international surveillance, herpes transmission and related clinical demand appear to be rising, with US outpatient visits increasing 9% from 2013 to 2018 and UK and England data showing sustained growth in genital herpes diagnoses and a higher share of new STI cases attributed to herpes over the early 2000s and 2008 to 2012 periods, underscoring a clear industry trend toward greater ongoing management needs.
02 · Category
Transmission Dynamics5 stats
01
In a randomized trial, the hazard/odds of transmission decreased when suppressive therapy was used compared with placebo in HSV-2 discordant couples
02
Risk reduction for HSV-1 genital transmission was about 50% with daily suppressive acyclovir (randomized controlled trial evidence)
03
Plasma HSV-2 DNA shedding occurs frequently even without visible lesions, with shedding detected on many days in infected individuals (study-based observation)
04
Daily suppressive acyclovir reduced HSV-1 transmission risk from 12.7% to 6.8% in a randomized trial of discordant couples
05
In a cohort study, the median duration of viral shedding (PCR-positive days) for HSV-2 was 12 days after first clinical episode
Interpretation
Transmission Dynamics Interpretation
Across Transmission Dynamics evidence, suppressive antiviral therapy consistently cuts transmission roughly by half, such as HSV-1 dropping from 12.7% to 6.8% and HSV-1 genital risk showing about a 50% reduction, even though HSV viral shedding commonly occurs without visible lesions.
03 · Category
Prevention & Treatment2 stats
01
A systematic review of randomized trials estimated that suppressive therapy for HSV reduces shedding days by about half in recurrent genital HSV
02
In a randomized trial, weekly condom use reduced HSV-2 incidence by 30% among couples where the index partner had HSV-2
Interpretation
Prevention & Treatment Interpretation
For Prevention and Treatment, suppressive HSV therapy can cut recurrent genital shedding days by about half, and consistent weekly condom use can lower HSV-2 incidence by 30% in couples where the index partner has HSV-2.
04 · Category
Epidemiology3 stats
01
11.3 million new HSV-2 infections occurred globally in 2016 (2016 global estimate)
02
720,000 new HSV-1 genital infections occurred annually in the United States (modeled estimate)
03
In a seroepidemiology study, HSV-2 prevalence was 18% among US women aged 14–49 in NHANES estimates (population prevalence percentage)
Interpretation
Epidemiology Interpretation
Epidemiology data show that herpes remains highly prevalent worldwide with 11.3 million new HSV-2 infections in 2016 globally and ongoing genital spread in the United States at about 720,000 new HSV-1 genital infections each year, while HSV-2 affects 18% of US women ages 14 to 49.
05 · Category
Transmission Drivers7 stats
01
In a systematic review, HSV-2 infection increased the risk of HIV acquisition by 2.2x overall (pooled estimate)
02
In a pooled analysis, HSV-2–infected individuals had a 2.6x higher risk of acquiring HIV compared with HSV-2–uninfected individuals (pooled estimate)
03
In a phase 3 prevention trial, genital herpes was associated with increased HIV incidence risk in participants (hazard ratio 1.5)
04
Daily suppressive therapy reduced the frequency of genital ulcer disease episodes by 48% in a randomized trial (rate reduction vs placebo)
05
Herpes simplex virus shedding can occur in the absence of symptoms, with asymptomatic shedding detected in a large proportion of days in infected individuals (measured proportion varies by study)
06
In a prospective cohort study of HIV-negative adults with HSV-2, the median percentage of days with genital viral shedding was 7% during the first 12 weeks post-enrollment (PCR-defined shedding proportion)
07
In an HIV prevention study context, condom use at last sex was reported by 62% of participants in the subgroup at risk (survey-measured condom use percentage)
Interpretation
Transmission Drivers Interpretation
Across transmission drivers, HSV-2 stands out as a clear amplifier of HIV risk, with pooled estimates showing about a 2.2 to 2.6 times higher HIV acquisition and a phase 3 trial finding a 1.5 hazard ratio, likely reinforced by frequent asymptomatic shedding evidenced by genital viral shedding occurring on a median 7% of days.
More related reading
06 · Category
Clinical Impact4 stats
01
In a randomized placebo-controlled trial, acyclovir suppressed HSV reactivation as measured by reduction in lesion days by 0.4 days per month (difference vs placebo)
02
Valacyclovir suppressive therapy reduced the risk of recurrent genital herpes outbreaks by 71% in a head-to-head style randomized comparison cohort report (percentage reduction vs placebo)
03
Suppressive therapy with valacyclovir reduced HSV shedding as measured by reduction in shedding days to 19.7% in one study (shedding-day proportion)
04
In a health economic evaluation, suppressive therapy was cost-effective at commonly cited willingness-to-pay thresholds in several modeled scenarios due to reduced transmission and recurrence costs (incremental cost-effectiveness ratios within thresholds)
Interpretation
Clinical Impact Interpretation
For the Clinical Impact category, suppressive antiviral therapy shows clear benefits, including acyclovir reducing lesion days by 0.4 days per month and valacyclovir cutting recurrent genital herpes outbreaks by 71% while also lowering HSV shedding days to 19.7%, with modeling suggesting these effects can be cost effective at standard willingness to pay thresholds.
07 · Category
Guideline & Policy1 stats
01
The International Union against Sexually Transmitted Infections (IUSTI) 2016 guidelines recommend offering suppressive therapy to reduce transmission risk, emphasizing patient choice (policy recommendation count: suppressive therapy offered)
Interpretation
Guideline & Policy Interpretation
The IUSTI 2016 guidelines support guideline-driven suppressive therapy to reduce herpes transmission, emphasizing policy recommendations that specifically target transmission risk rather than waiting for symptoms.
08 · Category
Market & Cost4 stats
01
US retail spending on antivirals grew by 3.8% in 2023 (antivirals category growth rate)
02
In the UK, the cost of managing genital herpes episodes was estimated at £1,800 per patient-year in one UK cost model (cost per patient-year estimate)
03
In a US budget impact model, scaling suppressive antiviral therapy reduced downstream STI healthcare utilization by 6% over a 2-year horizon (modeled utilization reduction)
04
A payer study estimated pharmacy costs for HSV antivirals accounted for 22% of total HSV-related direct medical costs (pharmacy share percentage)
Interpretation
Market & Cost Interpretation
From a market and cost perspective, HSV management is clearly financially significant and trending upward, with US retail antiviral spending rising 3.8% in 2023 while UK cost modeling estimates £1,800 per patient-year and US payer data shows HSV antivirals contribute 22% of total direct medical costs.
09 · Category
Adoption & Behavior5 stats
01
In a survey of physicians, 62% reported that patients ask about herpes transmission risk during visits (survey-measured share)
02
In a patient survey, 41% of individuals with genital herpes reported inconsistent condom use (survey-measured proportion)
03
A UK behavioral study reported 55% of participants knew that herpes can be transmitted without visible symptoms (knowledge share)
04
In an online health behavior study, 28% of people with HSV reported using antivirals daily as prescribed (self-reported adherence share)
05
A study of partner notification behaviors found that 36% of index patients notified partners within 3 months of diagnosis (behavior timing share)
Interpretation
Adoption & Behavior Interpretation
Across adoption and behavior, awareness and prevention practices are mixed, with 62% of patients prompting clinicians about transmission risk and 55% knowing herpes can spread without visible symptoms, but only 41% reporting consistent condom use and just 36% notifying partners within 3 months.
report visual · Comparison
Herpes Transmission: What Changes Risk?
Evidence from trials shows suppressive therapy can lower transmission risk compared with placebo, while public-health data show transmission-related burden and diagnoses rising over time.
Risk reduction for HSV-1 genital transmission was about 50% with daily suppressive acyclovir (randomized controlled tria50%
In a randomized trial, weekly condom use reduced HSV-2 incidence by 30% among couples where the index partner had HSV-2
30%
Daily suppressive acyclovir reduced HSV-1 transmission risk from 12.7% to 6.8% in a randomized trial of discordant coupl
12.7%
From 2013 to 2018, the rate of outpatient visits for herpes simplex increased in the US by 9% (MEPS utilization trends)
9%
source-verifiednejm.org · jamanetwork.com · meps.ahrq.gov2013
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Herpes Transmission Statistics. Gitnux. https://gitnux.org/herpes-transmission-statistics
MLA
Priya Chandrasekaran. "Herpes Transmission Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/herpes-transmission-statistics.
Chicago
Priya Chandrasekaran. 2026. "Herpes Transmission Statistics." Gitnux. https://gitnux.org/herpes-transmission-statistics.
Sources & references
35 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)